Vadim S. Koshkin, MD

Vadim Koshkin, MD, is an associate professor of medicine in the Division of Hematology and Oncology in the Department of Medicine at the University of California, San Francisco (UCSF) School of Medicine, as well as a genitourinary medical oncologist at the UCSF Helen Diller Comprehensive Cancer Center

Articles by Vadim S. Koshkin, MD

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Vadim Koshkin, MD, associate professor, medicine, Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco (UCSF) School of Medicine, genitourinary medical oncologist, UCSF Helen Diller Comprehensive Cancer Center

Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD

ByChandler Park, MD, MSc, FACP,Vadim S. Koshkin, MD

April 14th 2025

Drs Park and Koshkin explore the clinical implications of the phase 3 NIAGARA trial for patients with resectable bladder cancer.

Innovative Research Raises Questions About the Role of ADCs in Bladder Cancer: With Chandler Park, MD; and Vadim Koshkin, MD

ByChandler Park, MD, MSc, FACP,Vadim S. Koshkin, MD

April 9th 2025

Drs Park and Koshkin discuss sequencing antibody-drug conjugates for bladder cancer and the potential future role of sacituzimab govitecan in this disease.

ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD

ByChandler Park, MD, MSc, FACP,Vadim S. Koshkin, MD

April 3rd 2025

Drs Park and Koshkin discuss the benefits of enfortumab vedotin in bladder cancer and the potential for more ADCs to join the treatment paradigm.

Treating R/R Advanced Bladder Cancer With Novel Sequencing Strategies

ByVadim S. Koshkin, MD

February 7th 2022

UCSF Health’s Vadim S. Koshkin, MD, highlights approaches for sequencing novel therapies into treatment algorithms for patients with relapsed/refractory advanced bladder cancer.

Latest Updated Articles

Treating R/R Advanced Bladder Cancer With Novel Sequencing Strategies
Published: February 7th 2022 | Updated:

Vadim S. Koshkin, MD

Articles by Vadim S. Koshkin, MD

Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD

Innovative Research Raises Questions About the Role of ADCs in Bladder Cancer: With Chandler Park, MD; and Vadim Koshkin, MD

ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD

Treating R/R Advanced Bladder Cancer With Novel Sequencing Strategies

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma